Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction

Early, Amy P.; Moon, Wong

doi:10.1016/j.clbc.2020.07.015

Cited by 7 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 48 studies 4,9,11,13,19–62 met the inclusion criteria. Additional data was requested for 65 studies (Table S2) of whom seven (10.8%) 8,60,63–68 provided data, enabling inclusion of these studies in analyses. In total, 55 studies 4,8,9,11,13,19–68 were selected for qualitative synthesis (Tables 2–4).…”

Section: Resultsmentioning

confidence: 99%

“…Locoregional recurrence after autologous PMBR was reported by 16 studies 8,13,21,22,28,30,[40][41][42]52,58,[63][64][65]67,68 (Fig. 2C, I 2 = 72.2% [95% CI, 55.3%-82.6%]).…”

Section: Table 1 Risk Of Bias Appraisal Following the Methological In...mentioning

confidence: 99%

“…All included studies were published between February 2003 43 and October 2020 68 (Table 2). Among the 55 studies, 48 studies (87.3%) 4,8,9,11,13,[19][20][21][22][23][25][26][27][28][29][30][31][32]34,36,[38][39][40][41][43][44][45][46][47][48][49][50][51][52][53][54][56][57][58][60][61][62][63][64][65][66][67][68] were retrospective and seven (12.7%) …”

Section: Study Characteristics and Quality Of Evidencementioning

confidence: 99%

“…Twenty studies 20,31,[33][34][35][36]38,[41][42][43]46,48,53,[57][58][59]64,[66][67][68] (I 2 = 89.2% [95% CI, 84.7%-92.3%]) reported overall recurrences after implant-based PMBR, of which 19 studies 48,[50][51][52][53]55,[58][59][60]63,65,70,[74][75][76]89,98,100,109 (T 2 = 0.32) reported data on a3018 patients after I-IBR (Fig. 3E) with 353 recurrences (11.7%) (Table S3b).…”

Section: Immediate Versus Delayed Implant-based Pmbrmentioning

confidence: 99%

See 3 more Smart Citations

Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction—A systematic review and meta‐analysis

Bargon

Young‐Afat

Ikinci

et al. 2022

Cancer

View full text Add to dashboard Cite

BACKGROUND: Oncological safety of different types and timings of PMBR after breast cancer remains controversial. Lack of stratified risk assessment in literature makes current clinical and shared decision-making complex. This is the first systematic review and meta-analysis to evaluate differences in oncological outcomes after immediate versus delayed postmastectomy breast reconstruction (PMBR) for autologous and implant-based PMBR separately. METHODS: A systematic literature search was performed in MEDLINE, Cochrane Library, and Embase. The Cochrane Collaboration Handbook and Meta-analysis Of Observational Studies in Epidemiology checklist were followed for data abstraction. Variability in point estimates attributable to heterogeneity was assessed using I 2 -statistic. (Loco)regional breast cancer recurrence rates, distant metastasis rates, and overall breast cancer recurrence rates were pooled in generalized linear mixed models using random effects. RESULTS: Fifty-five studies, evaluating 14,217 patients, were included. When comparing immediate versus delayed autologous PMBR, weighted average proportions were: 0.03 (95% confidence interval [CI], 0.02-0.03) versus 0.02 (95% CI, 0.01-0.04), respectively, for local recurrences, 0.02 (95% CI, 0.01-0.03) versus 0.02 (95% CI, 0.01-0.03) for regional recurrences, and 0.04 (95% CI, 0.03-0.06) versus 0.01 (95% CI, 0.00-0.03) for locoregional recurrences. No statistically significant differences in weighted average proportions for local, regional and locoregional recurrence rates were observed between immediate and delayed autologous PMBR. Data did not allow comparing weighted average proportions of distant metastases and total breast cancer recurrences after autologous PMBR, and of all outcome measures after implant-based PMBR. CONCLUSIONS: Delayed autologous PMBR leads to similar (loco)regional breast cancer recurrence rates compared to immediate autologous PMBR. This study highlights the paucity of strong evidence on breast cancer recurrence after specific types and timings of PMBR.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Locoregional recurrence after autologous PMBR was reported by 16 studies 8,13,21,22,28,30,[40][41][42]52,58,[63][64][65]67,68 (Fig. 2C, I 2 = 72.2% [95% CI, 55.3%-82.6%]).…”

Section: Table 1 Risk Of Bias Appraisal Following the Methological In...mentioning

confidence: 99%

Section: Study Characteristics and Quality Of Evidencementioning

confidence: 99%

Section: Immediate Versus Delayed Implant-based Pmbrmentioning

confidence: 99%

See 2 more Smart Citations

Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction—A systematic review and meta‐analysis

Bargon

Young‐Afat

Ikinci

et al. 2022

Cancer

View full text Add to dashboard Cite

show abstract

“…Besides its role in energy metabolism, GAPDH can also interfere with the cancer cells' destiny, for which GAPDH is able to serve as a regulator of cell death. So some studies have regarded GAPDH as an alternative therapeutic target (Early and Moon, 2021;Trayes and Cokenakes, 2021). As found by biomedical images, MMP9 is an extracellular matrix associated with stromal cell protein that promotes tumor progression and regulates the activity of cell adhesion molecule and cytokines.…”

Section: Discussionmentioning

confidence: 99%

Differential Gene Analysis of Trastuzumab in Breast Cancer Based on Network Pharmacology and Medical Images

Liu

et al. 2022

Front. Physiol.

View full text Add to dashboard Cite

The purpose of this study was to use network pharmacology, biomedical images and molecular docking technology in the treatment of breast cancer to investigate the feasible therapeutic targets and mechanisms of trastuzumab. In the first place, we applied pubchem swisstarget (http://www.swisstargetprediction.ch/), (https://pubchem.ncbi.nlm.nih.gov/) pharmmapper (http://lilab-ecust.cn/pharmmapper/), and the batman-tcm (http://bionet.ncpsb.org.cn/batman-tcm/) database to collect the trastuzumab targets. Then, in NCBI-GEO, breast cancer target genes were chosen (https://www.ncbi.nlm.nih.gov/geo/). The intersection regions of drug and disease target genes were used to draw a Venn diagram. Through Cytoscape 3.7.2 software, and the STRING database, we then formed a protein-protein interaction (PPI) network. Besides, we concluded KEGG pathway analysis and Geen Ontology analysis by using ClueGO in Cytospace. Finally, the top 5 target proteins in the PPI network to dock with trastuzumab were selected. After screening trastuzumab and breast cancer in databases separately, we got 521 target genes of the drug and 1,464 target genes of breast cancer. The number of overlapping genes was 54. PPI network core genes include GAPDH, MMP9, CCNA2, RRM2, CHEK1, etc. GO analysis indicated that trastuzumab treats breast cancer through abundant biological processes, especially positive regulation of phospholipase activity, linoleic acid metabolic process, and negative regulation of endothelial cell proliferation. The molecular function is NADP binding and the cellular component is tertiary granule lumen. The results of KEGG enrichment analysis exhibited four pathways related to the formation and cure of breast cancer, containing Drug metabolism, Glutathione metabolism, Pyrimidine metabolism and PPAR signaling pathway. Molecular docking showed that trastuzumab has good binding abilities with five core target proteins (GAPDH, MMP9, CCNA2, RRM2, CHEK1). This study, through network pharmacology and molecular docking, provides new pieces of evidence and ideas to understand how trastuzumab treats breast cancer at the gene level.

show abstract

Incidence of Nonkeratinocyte Skin Cancer After Breast Cancer Radiation Therapy

Rezaei,

Eid,

Tang

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportancePrevious studies have suggested that radiation therapy may contribute to an increased risk of subsequent nonkeratinocyte (ie, not squamous and basal cell) skin cancers.ObjectiveTo test the hypothesis that radiation therapy for breast cancer increases the risk of subsequent nonkeratinocyte skin cancers, particularly when these cancers are localized to the skin of the breast or trunk.Design, Setting, and ParticipantsThis population-based cohort study used longitudinal data from the Surveillance, Epidemiology, and End Results (SEER) Program for January 1, 2000, to December 31, 2019. The SEER database includes population-based cohort data from 17 registries. Patients with newly diagnosed breast cancer were identified and were evaluated for subsequent nonkeratinocyte skin cancer development. Data analysis was performed from January to August 2023.ExposuresRadiation therapy, chemotherapy, or surgery for breast cancer.Main Outcomes and MeasuresThe primary outcomes were standardized incidence ratios (SIRs) for subsequent nonkeratinocyte skin cancer development from 2000 to 2019 based on treatment type (radiation therapy, chemotherapy, or surgery), skin cancer site on the body, and skin cancer subtype.ResultsAmong the 875 880 patients with newly diagnosed breast cancer included in this study, 99.3% were women, 51.6% were aged older than 60 years, and 50.3% received radiation therapy. A total of 11.2% patients identified as Hispanic, 10.1% identified as non-Hispanic Black, and 69.5% identified as non-Hispanic White. From 2000 to 2019, there were 3839 patients with nonkeratinocyte skin cancer, including melanoma (3419 [89.1%]), Merkel cell carcinoma (121 [3.2%]), hemangiosarcoma (104 [2.7%]), and 32 other nonkeratinocyte skin cancers (195 [5.1%]), documented to occur after breast cancer treatment. The risk of nonkeratinocyte skin cancer diagnosis after breast cancer treatment with radiation was 57% higher (SIR, 1.57 [95% CI, 1.45-1.7]) than that of the general population when considering the most relevant site: the skin of the breast or trunk. When risk at this site was stratified by skin cancer subtype, the SIRs for melanoma and hemangiosarcoma were both statistically significant at 1.37 (95% CI, 1.25-1.49) and 27.11 (95% CI, 21.6-33.61), respectively. Receipt of radiation therapy was associated with a greater risk of nonkeratinocyte skin cancer compared with chemotherapy and surgical interventions.Conclusions and RelevanceIn this study of patients with breast cancer, an increased risk of melanoma and hemangiosarcoma after breast cancer treatment with radiation therapy was observed. Although occurrences of nonkeratinocyte skin cancers are rare, physicians should be aware of this elevated risk to help inform follow-up care.

show abstract

Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction

Cited by 7 publications

References 36 publications

Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction—A systematic review and meta‐analysis

Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction—A systematic review and meta‐analysis

Differential Gene Analysis of Trastuzumab in Breast Cancer Based on Network Pharmacology and Medical Images

Incidence of Nonkeratinocyte Skin Cancer After Breast Cancer Radiation Therapy

Contact Info

Product

Resources

About